MedTrace Logo

Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment

NCT03431961 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-08-02

No results posted yet for this study

Summary

Subjects with allergic asthma developing the required nasal symptoms in response to nasal allergen titration during a screening period will be randomized 1:1 to one of 2 cohorts. All subjects will have repeated nasal challenges with allergen. One cohort will have nasal saline challenge as control. One cohort will have intranasal corticosteroid intervention.

Conditions

  • Allergic Asthma

Interventions

DRUG

Triamcinolone Acetonide

220 mcg administered twice daily for 14 days

DRUG

Placebo

twice daily for 14 days

Sponsors & Collaborators

  • Gail Gauvreau

    lead OTHER

Principal Investigators

  • Gail M Gauvreau, PhD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431961 on ClinicalTrials.gov